Perlin Bio

Edison Scientific, founded in 2024 in San Francisco, USA, uses AI to help biologists and chemists read papers faster, analyze data, and design experiments.

Helical, founded in 2024 in Luxembourg, converts biological AI foundation models into reproducible drug discovery workflows for pharmaceutical teams.

Onepot, founded in 2023 in South San Francisco, USA, synthesizes small molecules for drug discovery using AI-driven automated synthesis for biopharmaceutical companies.

Aether Biomachines, founded in 2017 in Menlo Park, uses AI and automation platforms for high-throughput design and evolution of industrial enzymes and proteins.

Network Bio is a Palo Alto, California biotechnology company founded in 2022 that builds disease-specific AI models from human biological data. Its vertically integrated platform combines a biological research network that sources, links and structures tissue, blood and longitudinal clinical outcomes from leading U.S. academic medical centers (Mass General Brigham, University of Pennsylvania, Duke University, University of Colorado Anschutz and UCSF, spanning 500,000+ patients across oncology, immunology, metabolic and cardiovascular disease) into AI-ready datasets, with a bio-native AI architecture purpose-built to learn from multimodal biological data, overcome technical confounders and batch effects, and generate interpretable representations of disease biology that generalize across diseases, tissues and modalities.

Generare, founded in 2023 in Paris, France, uses AI and synthetic biology to discover small molecules from microbial genomes for drug discovery.